SCHEMBL13696558

SCHEMBL13696558

CN(C)CCCNC(=O)C[C@@H]1[C@@H](Nc2nccc(N3CCCCCC3)n2)CCCN1C1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 6/20 0.38
▸ CXCR4 P61073 2/20 0.37
▸ CCNK O75909 1/20 0.35
▸ CDK12 Q9NYV4 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ ALK Q9UM73 3/20 0.34
▸ IGF1R P08069 1/20 0.34
▸ CDK2 P24941 1/20 0.33
▸ NEK2 P51955 1/20 0.33
▸ IRAK4 Q9NWZ3 1/20 0.33
▸ NAPEPLD Q6IQ20 1/20 0.33
▸ CCR4 P51679 1/20 0.32
▸ MAPK8 P45983 1/20 0.32
▸ MRGPRX1 Q96LB2 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ NR2C2 P49116 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2010696 1.00 HRH4 (0.38) HRH4CXCR4CCNKCDK12KDM4E
SCHEMBL13696542 0.90 CXCR4 (0.45) HRH4CXCR4CCNKCDK12ALK
SCHEMBL2012554 0.90 CXCR4 (0.45) HRH4CXCR4CCNKCDK12ALK
SCHEMBL14391832 0.90 CXCR4 (0.45) HRH4CXCR4CCNKCDK12ALK
SCHEMBL2011381 0.89 CXCR4 (0.45) HRH4CXCR4CCNKCDK12ALK
SCHEMBL13696544 0.89 CXCR4 (0.45) HRH4CXCR4CCNKCDK12ALK
SCHEMBL13696545 0.88 CXCR4 (0.49) HRH4CXCR4CCNKCDK12ALK
SCHEMBL2014223 0.88 CXCR4 (0.49) HRH4CXCR4CCNKCDK12ALK
SCHEMBL4119612 0.84 HRH4 (0.44) HRH4CXCR4MAPK8HRH3
SCHEMBL5581470 0.82 HRH4 (0.42) HRH4CXCR4CCNKCDK12KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF CXCR4, CXCR1, CXCL12 HRH4 152/4885CXCR4 1/4885CCNK 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback